Fatal liver failure after hepatitis B reactivation following chemotherapy for lymphoma in a patient with only anti-HBc antibody and review of the literature;Évolution fatale après réactivation d'une hépatite chronique virale B occulte dans les suites d'une chimiothérapie pour lymphome chez un malade porteur de l'anticorps anti-HBc isolé

Gastroenterologie Clinique et Biologique

Volumn 31, Issue 11, 2007, Pages 1028-1031

  Thirot Bidault, Anne ^a   Ben Mansour, Jaata ^a   Lambotte, Olivier ^a   Besson, Caroline ^a   Bou Farah, Rita ^a   Pallier, Coralie ^a   Buffet, Catherine ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEPATITIS B CORE ANTIBODY; LAMIVUDINE; PREDNISONE; RITUXIMAB; VALACICLOVIR; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; HEPATITIS B ANTIBODY; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; FATALITY; FEMALE; HEPATITIS B; HERPES LABIALIS; HODGKIN DISEASE; HUMAN; LIVER FAILURE; MULTIPLE CYCLE TREATMENT; SEROLOGY; SIDE EFFECT; URINARY TRACT INFECTION; VIRUS HEPATITIS; VIRUS LOAD; VIRUS REACTIVATION; BLOOD; DRUG EFFECT; IMMUNOLOGY; LARGE CELL LYMPHOMA; REVIEW; VIRUS ACTIVATION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FATAL OUTCOME; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PREDNISONE; VINCRISTINE; VIRUS ACTIVATION;

EID: 38149060076     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(07)78326-4     Document Type: Article

References (23)

1. Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002;3:333-40.
2. Hui CK, Cheung WW, Au WY, Lie AK, Zhang HY, Yueng YH, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005;54:1597-603.
3. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Gastroenterology 1991;100:182-8.
4. Rossi G. Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with hemato-oncological neoplasias treated with chemotherapy. Leuk Lymphoma 2003;44:759-66.
5. Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975;2:528-30.
6. McMahon BJ. Selecting appropriate management strategies for chronic hepatitis B: who to treat. Am J Gastroenterol 2006;101:S7-12.
7. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006;131:59-68.
8. Coiffier B. Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of lamivudine prophylaxis. Cancer Invest 2006;24:548-52.
9. Tsutsumi Y, Tanaka J, Kawamura T, Miura T, Kanamori H, Obara S, et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 2004;83:58-60.
10. Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005;11:189-91.
11. Zell JA, Yoon EJ, Ignatius Ou SH, Hoefs JC, Chang JC. Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab. Anticancer Drugs 2005;16:83-5.
12. Tsutsumi Y, Kawamura T, Saitoh S, Yamda M, Obara S, Miura T, et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004;45:627-9.
13. Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004;83:769-74.
14. Tsutsumi Y, Kawamura T, Mori A, Tanaka J, Asaka M, Imamura M, et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005;4:599-608.
15. Wasif Saif M, Little F, Hamilton JM, Allegra J, Wilson HW. Reactivation of chronic hepatitis B infection following intensive chemotherapy and successful treatment with lamivudine: A case report and review of the literature. Ann Oncol 2001;12:123-9.
16. Vassiliadis T, Garipidou V, Tziomalos K, Perifanis V, Giouleme O, Vakalopoulou S. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy - a prospective case series. Ann J Hematol 2005;80:197-203.
17. Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 1986;83:1627-31.
18. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002;100:391-6.
19. Marusawa H, Imoto S, Ueda Y, Chiba T. Reactivation of latently infected hepatitis B virus in a leukaemia patient with antibodies to hepatitis B core antigen. J Gastroenterol 2001;36:633-6.
20. Kawai Y, Ikegaya S, Hata M, Kawahito M, Imamura S, Yoshida H, et al. Successful lamivudine therapy for post-chemotherapeutic fulminant hepatitis B virus carrier with non-Hodgkin's lymphoma: case report and review of the literature. Ann Hematol 2001;80:482-4.
21. Cortelezzi A, Vigano M, Zilioli VR, Fantini NN, Pasquini MC, Deliliers GL, et al. Adefovir added to lamivudine for hepatitis B reNScurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. J Clin Virol. 2006;35:467-9.
22. Persico M, Persico E, Marzocchella C, Masarone M, La Mura V, Carrino F, et al. Role of occult infection of hepatitis b virus on virus reactivation occuring in non - Hodgkin lymphoma patients treated with chemotherapy (abstract). Hepatology 2005;42:984.
23. Niscola P, Maurillo L, Venditti A, Buccisano F, Piccioni D, Amadori S, et al. Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy. Leukemia 2005;19:1840-1.